Search Results

Search

Ethics Talk: Could Trusting Science Mean Not Trusting Some FDA Decisions?

Submitted by Audiey.Kao@ama… on

In this video and audio edition of Ethics Talk, journal editor in chief, Dr Audiey Kao, talks with Dr Caleb Alexander about the US Food and Drug Administration's controversial decision to approve aducanumab for the treatment of Alzheimer's Disease.

Click here to read the transcript.

G. Caleb Alexander, MD, MS is professor of epidemiology and medicine at Johns Hopkins Bloomberg School of Public Health.

Video

Recorded on June 22, 2021

 

Neurology Patient Care

Audio

 

Conflict of Interest Disclosure

Dr Alexander is past chair and current member of FDA's Peripheral and Central Nervous System Drugs Advisory Committee. He is a co-founding principal and equity holder in Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation. He was also a member of OptumRx's National Pharmacy and Therapeutics Committee.

Viewpoints expressed are those of interview participants and do not necessarily reflect the views and policies of the AMA.

Header Image image Issue Visibility and Measurability in Health Care Off

Ethics Talk: Embodied History, Health Justice, and COVID-19, Part 1

Submitted by Audiey.Kao@ama… on

In this video and audio edition of Ethics Talk, journal editor in chief, Dr Audiey Kao, talks with Dr Nancy Krieger about the population health impacts of historical injustices and structural racism.

Click here to read the transcript.

Nancy Krieger, PhD is a professor of social epidemiology in the Department of Social and Behavioral Sciences at the Harvard TH Chan School of Public Health.

Part 2 of this conversation is here.

Video

 

Professionalism

Audio

 

Conflict of Interest Disclosure
Interviewee had no conflicts of interest to disclose.

Viewpoints expressed are those of interview participants and do not necessarily reflect the views and policies of the AMA.

Header Image image Issue Opioids and Public Health CME Off
Letter to the Editor
Nov 2018

Added Points of Concern About Caring for Dying Patients

Annette Hanson, MD, Ron Pies, MD, and Mark Komrad, MD
Authors respond to “How Should Physicians Care for Dying Patients with Amyotrophic Lateral Sclerosis?” by arguing that patients’ motives for accessing death with dignity laws should be thoroughly explored and that temporarily limiting patient autonomy can promote well-being at the end of life.
AMA J Ethics. 2018; 20(11):E1107-1109. doi: 10.1001/amajethics.2018.1107.
Letter to the Editor
Nov 2018

Response to “Added Points of Concern About Caring for Dying Patients”

Alexander Craig, MPhil and Elizabeth Dzeng, MD, PhD, MPH
Responding to “Added Points of Concern about Caring for Dying Patients,” authors argue that physicians’ refusal to prescribe lethal drugs in accordance with states’ death with dignity laws could damage patient-physician relationships and harm patients.
AMA J Ethics. 2018; 20(11):E1110-1112. doi: 10.1001/amajethics.2018.1110.
Case and Commentary
Sep 2019

How Should We Decide Whether and When Some Care Is Better Than No Care?

Rachel Koch, MD, John G. Meara, MD, DMD, MBA, and Anji E. Wall, MD, PhD
Single-procedure interventions with minimal follow-up and clear quality-of-life gain are well suited for surgical mission trips. But not all risks and benefits are easily assessed.
AMA J Ethics. 2019; 21(9):E729-734. doi: 10.1001/amajethics.2019.729.
Case and Commentary
Oct 2019

How Should We Determine the Value of CAR T-Cell Therapy?

Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019; 21(10):E844-851. doi: 10.1001/amajethics.2019.844.